Feb 01, 2021 / 01:00PM GMT
Operator
Hello, and welcome to the Matinas BioPharma ENHANCE-IT Top Line Data Announcement Conference Call.
(Operator Instructions)
As a reminder, this conference is being recorded. I would now like to turn the conference over to Peter Vozzo, Investor Relations representative for Matinas BioPharma. You may begin.
Peter Vozzo - Westwicke Partners, LLC - MD
Thank you, Kevin. Good morning, everyone, and thank you for joining the Matinas BioPharma ENHANCE-IT Top Line Results Conference Call. Earlier this morning, we issued a press release containing the top line data from the ENHANCE-IT head-to-head study of LYPDISO versus Amarin Corporation's Vascepa. The press release is available under the Investors section of Matinas BioPharma's website, along with the slide deck to guide this morning's presentation.
Speaking on today's call will be Jerry Jabbour, Chief Executive Officer; and Dr. Terry Ferguson, Chief Medical Officer. Joining management on the call is Dr. John Kastelein, a respected key opinion leader and a member of Matinas BioPharma
Matinas BioPharma Holdings, Inc. - Special Call Transcript
Feb 01, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers